MNMDMind Medicine (MindMed) Inc.

Nasdaq mindmed.co


$ 6.36 $ -0.06 (-0.93 %)    

Friday, 16-Aug-2024 15:59:57 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 6.36
$ 6.36 x 500
-- x --
-- - --
$ 2.41 - $ 12.22
825,653
na
478.93M
$ 7.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mindmed-prices-public-offering-of-929m-common-shares-at-700-per-share-and-143m-pre-funded-warrants-at-6999-per-warrant

Expects Gross Proceeds Of Approximately $75M To Fund R&D And General Corporate Purposes

 mind-medicine-mindmed-inc-announces-proposed-public-offering-to-fund-the-research-and-development-of-its-product-candidates-terms-undisclosed

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical com...

 hc-wainwright--co-reiterates-buy-on-mind-medicine-maintains-35-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $35 price t...

 roth-mkm-maintains-buy-on-mind-medicine-maintains-36-price-target

Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

Core News & Articles

https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/

 groundbreaking-fentanyl-vaccine-being-developed-to-prevent-fatal-overdoses-startup-secures-10m

The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain.

 cantor-fitzgerald-reiterates-overweight-on-mind-medicine

Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.

 mindmed-reports-completion-of-end-of-phase-2-meeting-with-fda-says-reached-alignment-on-phase-3-development-strategy-for-mm120-in-generalized-anxiety-disorder

Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions ...

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

 rbc-capital-reiterates-outperform-on-mind-medicine-maintains-22-price-target

RBC Capital analyst Brian Abrahams reiterates Mind Medicine (NASDAQ:MNMD) with a Outperform and maintains $22 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION